Diane Christina Galistan

@dianegalistan

Singapore

Rates

Acceptable rate for a 500-word story: US$100 - US$300

Stats

Total briefs
27
Work samples
6

On the web

LinkedIn Website

Languages and expertise

English Mandarin
Science & Technology Biotech & Pharma Health & Wellness

About

.

Work Samples

Feature image
Press release www.prnewswire.com

GeneASIC Technologies to Exhibit New Genome Data Analysis System at CES 2022

GeneASIC Technologies will be walking into this year's CES 2022 arm in arm with its first product, the GeneASIC Next-Generation Sequencing Analysis Acceleration Platform (NGSAAP). The annual event deemed the most influential tech event and is a showcase of the latest innovation in design and engineering in the consumer technology segment.
Feature image
Press release www.prnewswire.com

Old Drugs Given New Life: Acura NanoMedicine Inc. Upgrades Existing Drugs Providing a More Efficient the Treatment for Cancer

Taiwanese company Acura NanoMedicine Inc (https://www.acura-nanomed.com/), an award-winning health tech and biomedicine company, announces a groundbreaking nanotech-based solution to reduce instances of drug resistance and give new life to cancer treatments.
Feature image
Press release www.prnewswire.com

RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome

RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, recently announced positive results from the completion of its Phase II trial in China for Telitacicept in the treatment of primary Sjögren's syndrome ("pSS").
Feature image
Press release www.prnewswire.com

Novel Herbal Drug by Xantho Biotechnology Seeks To Be New First-Line Atopic dermatitis Treatment

Botanical drug company Xantho Biotechnology has announced that its atopic dermatitis (AD) treatment, GM-XANTHO, has advanced to phase II of clinical trials. This comes after years of rigorous pre-clinical pharmacology, pharmacokinetics, and toxicity testing. The outcome is a product effective in treating AD that keeps side effects to a minimum.
Feature image
Press release www.bloomberg.com

RemeGen Reiterates Commitment to Its Battle Against Autoimmune Disease on World Strengthened Immunity Day 2021

To celebrate World Strengthened Immunity Day, RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, reiterated its commitment to discovering, developing, and producing best-in-class biological drugs for autoimmune diseases, to create clinical value, and meet the major unmet clinical needs of the world.
Feature image
Press release www.bloomberg.com

RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer

RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, today announced that two of its innovative drugs, a dual-targeted TACI-Fc fusion protein, Telitacicept (RC18) for treating systemic lupus erythematosus (SLE) and a novel antibody-drug conjugate (ADC), Disitamab Vedotin (RC48) for treating locally advanced or metastatic gastric cancer, have been officially included in this year's National Reimbursement Drug List (NRDL).